Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EPS (Basic): 2020-2024

Historic EPS (Basic) for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$2.56.

  • NewAmsterdam Pharma Co N.V's EPS (Basic) fell 238.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 8.89%. This contributed to the annual value of -$2.56 for FY2024, which is 19.07% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its EPS (Basic) stood at -$2.56 for FY2024, which was down 19.07% from -$2.15 recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's EPS (Basic)'s 5-year high stood at -$0.71 during FY2020, with a 5-year trough of -$3.81 in FY2021.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's EPS (Basic) had a median value of -$2.15 in 2023 and averaged -$1.97.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 438.21% in 2021, then skyrocketed by 68.77% in 2022.
  • NewAmsterdam Pharma Co N.V's EPS (Basic) (Yearly) stood at -$0.71 in 2020, then slumped by 438.21% to -$3.81 in 2021, then spiked by 68.77% to -$1.19 in 2022, then crashed by 80.67% to -$2.15 in 2023, then decreased by 19.07% to -$2.56 in 2024.